Herrera FC

No ORCID on file · 2 papers in corpus

rct 2025

Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study

Fertility and sterility ·doi:10.1016/j.fertnstert.2025.06.016

OBJECTIVE: To evaluate whether oral linzagolix administered once daily for up to 52 weeks (extension study) at a dose of 100 mg or 200 mg with or without hormonal add-back therapy (ABT) (1.0 mg estradiol; 0.5 mg norethisterone acetate) can …

2025

Pain Reduction in Linzagolix-Treated Patients With Uterine Fibroids: A Secondary Mediation Analysis of the PRIMROSE 1 and 2 Phase 3 Trials.

BJOG : an international journal of obstetrics and gynaecology ·doi:10.1111/1471-0528.18190

ObjectiveAmong women with uterine fibroids (UFs), we assess the extent to which the linzagolix effect on pain alleviation is explained by its effect on reducing heavy menstrual bleeding (HMB) and fibroid volume (FV).DesignPost hoc analysis …